Danilo Perrotti

Danilo Perrotti

UNVERIFIED PROFILE

Are you Danilo Perrotti?   Register this Author

Register author
Danilo Perrotti

Danilo Perrotti

Publications by authors named "Danilo Perrotti"

Are you Danilo Perrotti?   Register this Author

89Publications

3014Reads

19Profile Views

Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia".

Sci Transl Med 2019 Jul;11(501)

School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW 2308, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.aau0416DOI Listing
July 2019

Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay.

Curr Drug Targets 2017 ;18(4):377-388

Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1389450117666160615074120DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5970649PMC
September 2017

Twisting IL-1 signaling to kill CML stem cells.

Blood 2016 12;128(23):2592-2593

UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-10-741009DOI Listing
December 2016

c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias.

Mol Cancer Res 2015 Apr 31;13(4):699-712. Epub 2015 Mar 31.

Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland. Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-14-0422DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398615PMC
April 2015

From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies.

Front Oncol 2015 16;5:21. Epub 2015 Feb 16.

Department of Medicine, The Greenebaum Cancer Center, University of Maryland School of Medicine , Baltimore, MD , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2015.00021DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4329809PMC
March 2015

A "RANning" leap with "XPOrt" into TKI resistance.

Blood 2015 Mar;125(11):1686-8

UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-01-622217DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4357578PMC
March 2015

SETting OP449 into the PP2A-activating drug family.

Clin Cancer Res 2014 Apr 14;20(8):2026-8. Epub 2014 Mar 14.

Authors' Affiliations: The Ohio State University Comprehensive Cancer Center, Columbus, Ohio; and Department of Medicine, The Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/clincanres/20/
Web Search
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-14-0166DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286336PMC
April 2014

miR-29 acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR.

Sci Signal 2013 Jul 30;6(286):ra63. Epub 2013 Jul 30.

Department of Molecular Virology, Immunology, and Medical Genetics, Human Cancer Genetics Program, The Ohio State University, Columbus, OH 43210, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scisignal.2004177DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3885907PMC
July 2013

Protein phosphatase 2A: a target for anticancer therapy.

Lancet Oncol 2013 May;14(6):e229-38

Human Cancer Genetics Program, Department of Molecular Virology, Immunology, and Medical Genetics, and Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210-2207, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(12)70558-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913484PMC
May 2013

Unfolding tyrosine kinase inhibitor sensitivity in chronic myeloid leukemia.

Cell Cycle 2012 Dec 16;11(23):4300-1. Epub 2012 Nov 16.

Comprehensive Cancer Center, The Ohio State University, Columbus, OH USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cc.22808DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552908PMC
December 2012

Mutated beta-catenin evades a microRNA-dependent regulatory loop.

Proc Natl Acad Sci U S A 2011 Mar 7;108(12):4840-5. Epub 2011 Mar 7.

Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1101734108DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064338PMC
March 2011

The PP2A inhibitor SET regulates granzyme B expression in human natural killer cells.

Blood 2011 Feb 14;117(8):2378-84. Epub 2010 Dec 14.

Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University Comprehensive Cancer Center, 460 West 12th Ave., Columbus, OH 43210, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2010-05-285130DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062407PMC
February 2011

BCR-ABL1 kinase-dependent alteration of mRNA metabolism: potential alternatives for therapeutic intervention.

Leuk Lymphoma 2011 Feb 11;52 Suppl 1:30-44. Epub 2011 Jan 11.

Human Cancer Genetics Program, Depatment of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center and Center for RNA Biology, The Ohio State University, Columbus, OH 43210-2207, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2010.546914DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973825PMC
February 2011

Chronic myeloid leukemia: mechanisms of blastic transformation.

J Clin Invest 2010 Jul 1;120(7):2254-64. Epub 2010 Jul 1.

Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 41230, USA.

View Article

Download full-text PDF

Source
http://www.jci.org/articles/view/41246
Publisher Site
http://dx.doi.org/10.1172/JCI41246DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2898591PMC
July 2010

Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias.

Cancer Metastasis Rev 2008 Jun;27(2):159-68

Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics, and Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10555-008-9119-xDOI Listing
June 2008

Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease.

Cancer Cell 2007 Nov;12(5):467-78

Division of Experimental Hematology, Cincinnati Children's Research Foundation, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2007.10.015DOI Listing
November 2007

From mRNA metabolism to cancer therapy: chronic myelogenous leukemia shows the way.

Clin Cancer Res 2007 Mar;13(6):1638-42

The Molecular Biology and Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43240, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-2320DOI Listing
March 2007

Inducible activation of CEBPB, a gene negatively regulated by BCR/ABL, inhibits proliferation and promotes differentiation of BCR/ABL-expressing cells.

Blood 2006 May 17;107(10):4080-9. Epub 2006 Jan 17.

Department of Microbiology and Immunology, Kimmel Cancer Center, Thomas Jefferson Medical College, 233 South and 10th Street, Philadelphia, PA 19107, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2005-08-3181DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895282PMC
May 2006

Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes.

J Control Release 2006 May 6;112(2):199-207. Epub 2006 Mar 6.

Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2006.02.011DOI Listing
May 2006

The biology of CML blast crisis.

Blood 2004 Jun 24;103(11):4010-22. Epub 2004 Feb 24.

Department of Microbiology and Immunology, Kimmel Cancer Center, Thomas Jefferson Medical College, Philadelphia, PA 19107, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2003-12-4111DOI Listing
June 2004

Translational regulation by the p210 BCR/ABL oncoprotein.

Oncogene 2004 Apr;23(18):3222-9

Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics and the Comprehensive Cancer Center, The Ohio State University, Columbus OH 43210, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.onc.1207543DOI Listing
April 2004

Altered mRNA translation: possible mechanism for CML disease progression.

Cell Cycle 2003 May-Jun;2(3):177-80

Division of Human Cancer Genetics, Ohio State University, 440 Tzagournis Medical Research Bldg., 420 W. 12 Avenue, Columbus, OH 43210, USA.

View Article

Download full-text PDF

Source
September 2003

Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A. N. Mohamed et al., The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin. Cancer Res., 9: 1333-1337, 2003.

Clin Cancer Res 2003 Apr;9(4):1248-52

Division of Hematology and Oncology, Department of Internal Medicine, The James Cancer Hospital and The Comprehensive Cancer Center at The Ohio State University, Columbus, Ohio 43210, USA.

View Article

Download full-text PDF

Source
April 2003

CCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia.

Blood 2003 Feb 3;101(3):1141-8. Epub 2002 Oct 3.

Comprehensive Cancer Center and Department of Laboratory Medicine, University of California, San Francisco 94143-0128, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2002-05-1374DOI Listing
February 2003

BCR/ABL activates mdm2 mRNA translation via the La antigen.

Cancer Cell 2003 Feb;3(2):145-60

Department of Microbiology and Immunology, Kimmel Cancer Center, Thomas Jefferson Medical College, Philadelphia, PA 19107, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s1535-6108(03)00020-5DOI Listing
February 2003

Post-transcriptional mechanisms in BCR/ABL leukemogenesis: role of shuttling RNA-binding proteins.

Oncogene 2002 Dec;21(56):8577-83

Thomas Jefferson University, Department of Microbiology and Immunology, Kimmel Cancer Institute, Philadelphia, PA 19107, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.onc.1206085DOI Listing
December 2002

hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis.

Mol Cell Biol 2002 Apr;22(7):2255-66

Department of Microbiology and Immunology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC133663PMC
http://dx.doi.org/10.1128/mcb.22.7.2255-2266.2002DOI Listing
April 2002

BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2.

Nat Genet 2002 Jan 20;30(1):48-58. Epub 2001 Dec 20.

Department of Microbiology and Immunology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ng791DOI Listing
January 2002